Clinical trials: Pharmacogenetics
Multiple Sclerosis
Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)
This study, PRISMS-15 is a single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial.
- Trial name
- PRISMS-15 (NCT01034644)
- Where
- Switzerland
- Volunteers
- 290 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Obesity, Rhinitis
Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application
The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized…
- Conditions
- Obesity, Rhinitis, Rhinitis, Allergic, Respiratory Sounds
- Trial name
- NCT02758990
- Testing
- Vitamin A, Vitamin B6, Vitamin C
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Verifomics LLC
Idiopathic Growth Hormone Deficiency, Turner Syndrome
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
PREDICT Validation is a validation pharmacogenetic trial. The purpose of this study is to confirm that some genes can be used to predict how well a subject diagnosed with idiopathic growth hormone deficiency (IGHD) or turner…
- Trial name
- NCT01419249
- Testing
- Blood sampling
- Where
- 31 sites in Argentina, Canada and 7 more
- Volunteers
- 458 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Asthma
A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma
This is a multi-national, randomized, double-blind, 3-period crossover, incomplete block design to evaluate 5 once-daily and 2 twice-daily doses of GSK573719 in combination with placebo.
- Trial name
- NCT01641692
- Testing
- GSK573719 (Sub-group cohort), Salbutamol/Albuterol
- Where
- 43 sites in United States, Bulgaria and 4 more
- Volunteers
- 350 people
- Sponsor
- GlaxoSmithKline
Anemia, Cardiovascular Disease
An Exploratory Sub-study for the RED-HF™ (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial
The purpose of Study 20060172 was to measure echocardiographic parameters and biomarkers in a subgroup of study subjects enrolled in Study 20050222 (the RED-HF Trial).
- Conditions
- Anemia, Cardiovascular Disease, Congestive Heart Failure, Heart Failure
- Trial name
- NCT00534456
- Testing
- Darbepoetin alfa
- Volunteers
- 12 people
- Sponsor
- Amgen
Kidney Transplantation
Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.
This study will determine which, if any, allelic variants of mycophenolic acid (MPA) metabolizing enzymes, drug transporters and drug targets are associated with the observed variation in pharmacokinetic and pharmacodynamic…
- Trial name
- NCT00337493
- Testing
- mycophenolate mofetil [CellCept], Cyclosporine or tacrolimus
- Where
- 20 sites in United States
- Volunteers
- 155 people
- Sponsor
- Hoffmann-La Roche